---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-072871"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:47:52.354612+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics prices $100M equity offering and private placement

## Summary
- Underwritten offering of 14,545,454 shares at $5.50/share; net proceeds ~$74.7M.
- Concurrent private placement of pre-funded warrants to Redmile for ~$20M at $5.499/warrant.
- Total gross proceeds ~$100M; expected close March 21, 2024.
- Net proceeds to fund clinical trials, manufacturing, and working capital.
- BofA Securities, Jefferies, Leerink Partners act as joint bookrunners.

## SEC filing metadata
- accession: 0001193125-24-072871
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/0001193125-24-072871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/d799248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-072871
- JSON: https://secwatch.observer/filing/0001193125-24-072871.json
- Plain text: https://secwatch.observer/filing/0001193125-24-072871.txt

## Key facts
- Material Agreements
  FATE THERAPEUTICS INC entered into Underwriting Agreement with BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC valued at $74.7 million (effective 2024-03-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC
  - Value: $74.7 million
  - Effective: 2024-03-19
  source text: On March 19, 2024, Fate Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 14,545,454 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), at an offering price of $5.50 per Share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/0001193125-24-072871-index.htm
- Material Agreements
  FATE THERAPEUTICS INC entered into Securities Purchase Agreement with a fund affiliated with Redmile Group, LLC valued at approximately $20.0 million (effective 2024-03-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a fund affiliated with Redmile Group, LLC
  - Value: approximately $20.0 million
  - Effective: 2024-03-19
  source text: On March 19, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a fund affiliated with Redmile Group, LLC (collectively, “Redmile”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/0001193125-24-072871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.